JP2021501785A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501785A5
JP2021501785A5 JP2020524812A JP2020524812A JP2021501785A5 JP 2021501785 A5 JP2021501785 A5 JP 2021501785A5 JP 2020524812 A JP2020524812 A JP 2020524812A JP 2020524812 A JP2020524812 A JP 2020524812A JP 2021501785 A5 JP2021501785 A5 JP 2021501785A5
Authority
JP
Japan
Prior art keywords
alkyl
formula
substituted
group
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020524812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501785A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058972 external-priority patent/WO2019090088A1/en
Publication of JP2021501785A publication Critical patent/JP2021501785A/ja
Publication of JP2021501785A5 publication Critical patent/JP2021501785A5/ja
Pending legal-status Critical Current

Links

JP2020524812A 2017-11-02 2018-11-02 統合的ストレス経路の調節剤 Pending JP2021501785A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762580755P 2017-11-02 2017-11-02
US62/580,755 2017-11-02
US201862643075P 2018-03-14 2018-03-14
US62/643,075 2018-03-14
PCT/US2018/058972 WO2019090088A1 (en) 2017-11-02 2018-11-02 Modulators of the integrated stress pathway

Publications (2)

Publication Number Publication Date
JP2021501785A JP2021501785A (ja) 2021-01-21
JP2021501785A5 true JP2021501785A5 (cg-RX-API-DMAC7.html) 2021-12-09

Family

ID=64572460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524812A Pending JP2021501785A (ja) 2017-11-02 2018-11-02 統合的ストレス経路の調節剤

Country Status (9)

Country Link
US (1) US11939320B2 (cg-RX-API-DMAC7.html)
EP (1) EP3704115B1 (cg-RX-API-DMAC7.html)
JP (1) JP2021501785A (cg-RX-API-DMAC7.html)
CN (1) CN112166113A (cg-RX-API-DMAC7.html)
AU (1) AU2018358160B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020008834A2 (cg-RX-API-DMAC7.html)
CA (1) CA3080971A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020004557A (cg-RX-API-DMAC7.html)
WO (1) WO2019090088A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12157690B2 (en) 2015-12-09 2024-12-03 Microbial Discovery Group Llc Cold temperature-resistant microbials and methods of their use
WO2017151608A1 (en) 2016-02-29 2017-09-08 Microbial Discovery Group Llc Direct-fed microbials
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
US11166942B2 (en) 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
SG11202101486RA (en) 2018-08-16 2021-03-30 Innate Tumor Immunity Inc Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
WO2020072578A1 (en) 2018-10-02 2020-04-09 Microbial Discovery Group, Llc Microbials for animals
TW202545902A (zh) 2018-10-11 2025-12-01 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
CR20210426A (es) 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
US20220177456A1 (en) * 2019-03-06 2022-06-09 Denali Therapeutics Inc. Compounds, compositions and methods
MX2021012904A (es) 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
WO2020216766A1 (en) 2019-04-23 2020-10-29 Evotec International Gmbh Modulators of the integrated stress response pathway
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
MX2022002101A (es) 2019-08-22 2022-03-17 Microbial Discovery Group Llc Metodos de inhibicion con cepas microbianas y antibioticos.
CA3162526A1 (en) 2020-01-28 2021-08-05 Christopher John Brown Modulators of the integrated stress response pathway
KR20220151635A (ko) 2020-03-11 2022-11-15 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
US12514885B2 (en) 2020-08-21 2026-01-06 Microbial Discovery Group, Llc Microbials and antibiotics
BR112023002974A2 (pt) 2020-08-21 2023-04-04 Microbial Discovery Group Llc Cepas microbianas e antibióticos
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
MX2023004677A (es) 2020-10-22 2023-05-24 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式
CN118434749A (zh) * 2021-12-23 2024-08-02 新魁特株式会社 有机铜化合物以及有机铜化合物的制造方法
CN119744842B (zh) * 2024-12-31 2026-04-21 浙江省淡水水产研究所 饲料驯化后的翘嘴鳜的精子低温保存与超低温保存方法

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1026506A (en) 1962-10-17 1966-04-20 Du Pont Bicyclodiamines and preparation thereof
US3264351A (en) 1964-07-08 1966-08-02 American Home Prod 1, 4-diaminobicyclo [2.2.2] octanes
US3301827A (en) 1965-05-07 1967-01-31 Du Pont Polymers from polycyclic reactants having functional substituents on bridgehead carbon atoms
US3967629A (en) 1973-10-01 1976-07-06 International Flavors & Fragrances Inc. Bicyclic fragrance materials and processes therefor
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPH02215779A (ja) 1989-02-14 1990-08-28 Kuraray Co Ltd カルボン酸アミド誘導体類及びその医薬用途
US5047406A (en) 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JPH0592921A (ja) 1991-05-17 1993-04-16 Yamanouchi Pharmaceut Co Ltd シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤
US5852192A (en) 1992-03-11 1998-12-22 Dr. Karl Thomae Gmbh Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US5506257A (en) 1992-03-26 1996-04-09 University Of British Columbia Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
US5686454A (en) 1993-07-16 1997-11-11 Merck & Co., Inc. Camphorcarbonyl
DE4429079A1 (de) 1994-08-17 1996-02-22 Thomae Gmbh Dr K Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TWI259079B (en) * 2002-02-08 2006-08-01 Merck & Co Inc N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives
DE60303441T2 (de) * 2002-02-08 2006-09-21 Merck & Co., Inc. N-biphenylmethylaminocycloalkancarboxamid-derivative
WO2004050024A2 (en) 2002-11-27 2004-06-17 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
EP1571146A4 (en) 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US20070185079A1 (en) 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
AU2005212073B2 (en) 2004-02-18 2010-07-08 Kyorin Pharmaceutical Co., Ltd. Bicyclic amide derivatives
CA2594116A1 (en) 2005-01-05 2006-07-13 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2007005214A1 (en) 2005-06-29 2007-01-11 Janssen Pharmaceutica, N.V. Substituted {4(4-phenyl-piperazin-1yl)-cyclohexyl}-urea compounds
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
JP2009190971A (ja) 2006-06-06 2009-08-27 Mitsubishi Tanabe Pharma Corp 2−シアノピロリジン誘導体
WO2008075196A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives
CN101878216B (zh) 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
MY151986A (en) 2008-07-25 2014-07-31 Lundbeck & Co As H Adamantyl diamide derivatives and uses of same
ES2668834T3 (es) 2008-09-08 2018-05-22 Merck Serono Sa Pirimidinas macrociclicas como inhibidores de proteína quinasas
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
AU2010234087B2 (en) 2009-04-02 2016-05-12 Merck Patent Gmbh Piperidine and piperazine derivatives as autotaxin inhibitors
WO2011087758A1 (en) 2009-12-22 2011-07-21 H. Lundbeck A/S Adamantyl amide derivatives and uses of same
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
WO2011159854A1 (en) 2010-06-17 2011-12-22 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of ccr2
TWI538905B (zh) 2010-12-22 2016-06-21 H 朗德貝克公司 雙環[3.2.1]辛基醯胺衍生物及其用途
US8569283B2 (en) 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
EP2822944A1 (en) 2012-03-05 2015-01-14 Amgen, Inc. Oxazolidinone compounds and derivatives thereof
WO2013161980A1 (ja) * 2012-04-27 2013-10-31 東レ株式会社 シクロヘキサンジアミド誘導体及びその医薬用途
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
WO2014144952A2 (en) 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
US9580459B2 (en) 2013-04-26 2017-02-28 Metselex, Inc. Water-soluble ursodeoxycholic acid prodrugs
WO2015038778A1 (en) 2013-09-11 2015-03-19 The Brigham And Women's Hospital, Inc. SUBSTITUTED UREA EIF2α KINASE ACTIVATORS
JP2015199722A (ja) 2014-04-02 2015-11-12 大日本住友製薬株式会社 イミダゾール誘導体からなる医薬
MX358346B (es) 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
US20150362847A1 (en) 2014-06-13 2015-12-17 Canon Kabushiki Kaisha Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
JP2018520992A (ja) 2015-05-05 2018-08-02 バイエル ファーマ アクチエンゲゼルシャフト アミドで置換されているシクロヘキサン誘導体
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
US20190022071A1 (en) * 2015-08-31 2019-01-24 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
TW201722958A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
EP3350165B1 (en) 2015-09-16 2023-07-26 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI920577B (zh) 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
RU2018145734A (ru) 2016-06-08 2020-07-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения в качестве ингибиторов atf4 пути
US10526294B2 (en) 2016-06-24 2020-01-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepines and conjugates thereof
CN106349130B (zh) 2016-08-25 2018-01-23 潍坊大有生物化工有限公司 一种新的氟苯尼考的合成方法
EP4306166A3 (en) 2016-12-23 2024-06-26 Aquinnah Pharmaceuticals Inc. Compounds, compositions and methods of use
CN110730777A (zh) 2017-06-07 2020-01-24 葛兰素史密斯克莱知识产权发展有限公司 作为atf4通路抑制剂的化学化合物
US10435399B2 (en) 2017-07-31 2019-10-08 Takeda Pharmaceutical Company Limited HDAC6 inhibitory heterocyclic compound
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
EP3704125B1 (en) 2017-11-02 2026-03-11 Calico Life Sciences LLC Modulators of the integrated stress pathway
MX2020004538A (es) 2017-11-02 2020-09-18 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
SG11202004009TA (en) 2017-11-02 2020-05-28 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
BR112020008825A2 (pt) 2017-11-02 2020-10-20 Calico Life Sciences Llc moduladores da via de estresse integrada
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
MX2020004537A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía integrada del estrés.
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
WO2019183589A1 (en) 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
JP2021529814A (ja) 2018-07-09 2021-11-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 化学化合物
TW202545902A (zh) 2018-10-11 2025-12-01 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
MX2021013086A (es) 2019-04-30 2021-11-17 Aicuris Gmbh & Co Kg Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb).
AR118836A1 (es) 2019-04-30 2021-11-03 Calico Life Sciences Llc Moduladores de la vía de tensión integrada
PH12021552759A1 (en) 2019-04-30 2022-07-04 Abbvie Inc Substituted cycloalkyls as modulators of the integrated stress pathway
EP4237413A1 (en) 2020-10-30 2023-09-06 Calico Life Sciences LLC Modulators of the integrated stress pathway

Similar Documents

Publication Publication Date Title
JP2021501780A5 (cg-RX-API-DMAC7.html)
JP2021501787A5 (cg-RX-API-DMAC7.html)
JP2021501779A5 (cg-RX-API-DMAC7.html)
JP2021501789A5 (cg-RX-API-DMAC7.html)
JP2021501786A5 (cg-RX-API-DMAC7.html)
JP2021501790A5 (cg-RX-API-DMAC7.html)
JP2021501781A5 (cg-RX-API-DMAC7.html)
JP2021501788A5 (cg-RX-API-DMAC7.html)
JP2022530647A5 (cg-RX-API-DMAC7.html)
CN104837825B (zh) 鲁顿酪氨酸激酶抑制剂
RU2020117927A (ru) Модуляторы интегрированного стресса
JP6159484B2 (ja) グレリンo−アシルトランスフェラーゼ阻害剤
RU2020117900A (ru) Модуляторы интегрированного стресса
CN103214484A (zh) 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
JP2022505525A (ja) Nlrp活性に関連する状態を治療するための化合物及び組成物
JP4551402B2 (ja) ピラゾロ及びイミダゾ−ピリミジン誘導体
JP2021152056A (ja) 疾患を治療するためのmct4阻害剤
US12071438B2 (en) Crystal forms of an ALK2 inhibitor
HU228962B1 (en) Azolo triazines, pharmaceutical compositions containing them and use of the compounds
AU2020331330B2 (en) Fused ring heteroaryl compounds as ripk1 inhibitors
JP2018507899A (ja) 補体関連疾患の治療のための組成物および治療方法
JP7300552B2 (ja) 縮合環ピリミジンアミノ化合物、その調製方法、医薬組成物及び使用
TW202015693A (zh) 治療pi3k 相關病症之給藥方案
WO2017079753A1 (en) Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms
AU2020299526A1 (en) Bax inhibitors and uses thereof